What happened with ARAY today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Hospitals and stand-alone treatment facilities buy Accuray Incorporated’s equipment to treat cancer with radiation. Its platforms include CyberKnife and the TomoTherapy family, including Radixact, alongside software for treatment planning, imaging and data management. Customers pay for the systems and for installation, training and ongoing support. Services account for more revenue than product sales.
Most revenue comes from outside the United States, where Accuray sells both directly and through distributors. Its China joint venture, CNNC Accuray (Tianjin) Medical Technology Co. Ltd., distributes CyberKnife and Radixact and manufactures and sells Tomo C. The venture is also a significant customer of Accuray, making its purchasing decisions important to the business.
Equipment sales depend on providers securing funding, preparing treatment rooms and obtaining required permits or licenses; signed orders can be delayed or cancelled. Demand also depends on insurers and public healthcare payors covering radiation treatments. Accuray needs regulatory authorization to sell its devices in each market, and changes to products may require fresh approval. In China, customers also need licenses to use the equipment.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Accuray’s results hinge on radiotherapy-equipment spending and China shipment conditions; major equipment rivals to watch, Varian, owned by Siemens Healthineers, and Elekta, are absent from this list.
American Shared Hospital Services competes for hospitals’ radiation-treatment investment by leasing equipment and operating treatment facilities, while Accuray sells systems directly to hospitals and treatment facilities. Watch its equipment-leasing business for signs of hospitals choosing leases over buying from manufacturers, a choice that has cost it sales before.
Alpha Tau Medical Ltd. is developing radioactive sources inserted into solid tumors, offering a competing approach to Accuray’s systems that deliver radiation from outside the body, but it had no product-sales revenue through December 31, 2025. Watch Alpha DaRT’s development, regulatory approvals and commercialization rather than current sales for signs of this competitive threat taking shape.
GE HealthCare and Accuray both depend on hospital equipment budgets: GE HealthCare sells imaging equipment, while Accuray sells radiation-treatment systems, and the two also collaborate in cancer care. Watch GE HealthCare’s imaging-equipment sales for clues to hospital spending, which has already weighed on Accuray’s U.S. revenue as radiotherapy budgets and installation schedules tightened.
GE HealthCare Technologies Inc. earningsGEHC
GE HealthCare's imaging-equipment sales will show whether hospital equipment spending is firming, a clue to whether hospitals may be more willing to buy Accuray's radiation systems.
Look for improvement in GE HealthCare's imaging-equipment sales and any indication that hospitals are postponing purchases or projects. Stronger sales with fewer delays would suggest hospital equipment budgets may be easing, improving the setting for Accuray to win system orders and complete installations. Weaker sales or more delays would point to continued pressure on hospital capital spending and potentially on Accuray's purchasing and installation pace. This is an indirect signal, not a direct measure of radiotherapy budgets.
Accuray Incorporated earningsThis company
Accuray's report will show whether hospital orders are turning into radiation-system revenue and whether services can cushion weaker equipment sales.
Read product revenue and gross margin alongside orders and services revenue. Firm product revenue and orders would show demand converting into shipments. If orders hold but product revenue weakens, financing, treatment-room preparation or installation may be delaying revenue; if orders also weaken, demand itself is under pressure. If growing services still cannot offset weaker product sales, or gross margin falls further, profitability remains harder to restore.
American Shared Hospital Services earningsAMS
American Shared Hospital Services' equipment-leasing business will show whether hospitals are choosing its leased, operated treatment equipment over buying systems from manufacturers such as Accuray.
Check whether its equipment-leasing business is growing, alongside new projects or equipment deployments. Stronger leasing would suggest hospitals may prefer renting to buying, potentially crowding out Accuray's direct system sales. Weaker leasing would suggest less pull from that alternative, but would not by itself prove Accuray is winning more orders.
